Nothing Special   »   [go: up one dir, main page]

EP1128832A4 - Verbindungen, zusammenstellungen und methoden zur phophylaxe und behandlung von viralen infektionen und damit verbundenen erkrankungen - Google Patents

Verbindungen, zusammenstellungen und methoden zur phophylaxe und behandlung von viralen infektionen und damit verbundenen erkrankungen

Info

Publication number
EP1128832A4
EP1128832A4 EP99942288A EP99942288A EP1128832A4 EP 1128832 A4 EP1128832 A4 EP 1128832A4 EP 99942288 A EP99942288 A EP 99942288A EP 99942288 A EP99942288 A EP 99942288A EP 1128832 A4 EP1128832 A4 EP 1128832A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treating
compounds
methods
viral infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99942288A
Other languages
English (en)
French (fr)
Other versions
EP1128832A1 (de
Inventor
Thomas R Bailey
Dorothy C Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viropharma Biologics LLC
Original Assignee
Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viropharma Inc filed Critical Viropharma Inc
Publication of EP1128832A1 publication Critical patent/EP1128832A1/de
Publication of EP1128832A4 publication Critical patent/EP1128832A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP99942288A 1998-08-21 1999-08-19 Verbindungen, zusammenstellungen und methoden zur phophylaxe und behandlung von viralen infektionen und damit verbundenen erkrankungen Withdrawn EP1128832A4 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US9747698P 1998-08-21 1998-08-21
US97476P 1998-08-21
US11321298P 1998-12-22 1998-12-22
US113212P 1998-12-22
US11932899P 1999-02-09 1999-02-09
US119328P 1999-02-09
US13558599P 1999-05-24 1999-05-24
US13558699P 1999-05-24 1999-05-24
US135586P 1999-05-24
US135585P 1999-05-24
PCT/US1999/018785 WO2000010573A1 (en) 1998-08-21 1999-08-19 Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Publications (2)

Publication Number Publication Date
EP1128832A1 EP1128832A1 (de) 2001-09-05
EP1128832A4 true EP1128832A4 (de) 2003-03-05

Family

ID=27536838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99942288A Withdrawn EP1128832A4 (de) 1998-08-21 1999-08-19 Verbindungen, zusammenstellungen und methoden zur phophylaxe und behandlung von viralen infektionen und damit verbundenen erkrankungen

Country Status (10)

Country Link
EP (1) EP1128832A4 (de)
JP (1) JP2002523371A (de)
KR (1) KR20010099623A (de)
CN (1) CN1325309A (de)
AU (1) AU743411B2 (de)
BR (1) BR9913157A (de)
CA (1) CA2341970A1 (de)
ID (1) ID27787A (de)
IL (1) IL141456A0 (de)
WO (1) WO2000010573A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103562T2 (tr) * 1999-06-10 2002-04-22 Warner-Lambert Company Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
CA2383347A1 (en) 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
WO2001077091A2 (en) * 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
IL154993A0 (en) * 2000-09-29 2003-10-31 Neurogen Corp High affinity small molecule c5a receptor modulators
PL373912A1 (en) 2001-03-07 2005-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
US7265139B2 (en) 2001-03-08 2007-09-04 Incyte San Diego Inc. RXR activating molecules
GB2376944A (en) * 2001-05-18 2002-12-31 Pantherix Ltd Polycyclic heterocyclic compounds and their therapeutic use
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (de) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C Virus Polymerase Inhibitoren mit heterobicylischer Struktur
EP1429759A4 (de) 2001-09-26 2004-12-15 Bristol Myers Squibb Co Verbindungen zur behandlung des hepatitus c virus
JP2005513026A (ja) * 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
JP2005535593A (ja) * 2002-05-17 2005-11-24 キューエルティー インコーポレーティッド チアゾリジンジチオン誘導体の使用方法
ATE503764T1 (de) 2002-05-20 2011-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
EP1506000B9 (de) 2002-05-20 2011-08-31 Bristol-Myers Squibb Company Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
MXPA05000020A (es) 2002-07-01 2005-12-05 Pharmacia & Upjohn Co Llc Inhibidores de polimerasa ns5b de la infeccion del virus de la hepatitis c (hcv).
MXPA05000256A (es) 2002-07-01 2005-07-15 Upjohn Co Inhibidores de polimerasa ns5b del vhc.
FR2845000B1 (fr) 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
EA009847B1 (ru) * 2002-09-30 2008-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
WO2004043955A1 (en) * 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
ES2320771T3 (es) 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
DE602004025708D1 (de) 2003-07-11 2010-04-08 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
FR2858324A1 (fr) * 2003-07-30 2005-02-04 Centre Nat Rech Scient Nouveaux composes antibiotiques, compositions pharmaceutiques les contenant et leurs utilisations
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
US7566732B2 (en) 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101648944A (zh) 2004-02-20 2010-02-17 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
RS50815B (sr) 2004-02-24 2010-08-31 Japan Tobacco Inc. Kondenzovana heterotetraciklična jedinjenja i njihova upotreba kao inhibitora hcv polimeraza
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
JP2008540370A (ja) 2005-05-04 2008-11-20 エフ.ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス化合物
WO2006138118A2 (en) * 2005-06-15 2006-12-28 New York Blood Center Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8609668B2 (en) * 2006-05-04 2013-12-17 Philadelphia Health & Education Corporation Substituted triazolo[1,5-A]pyrimidines as antiviral agents
ES2358853T3 (es) 2006-10-10 2011-05-16 Medivir Ab Inhibidor nucleosídico de vhc.
WO2008082537A2 (en) * 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
JP5465666B2 (ja) 2007-06-29 2014-04-09 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス化合物
KR20100038417A (ko) 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP2011502998A (ja) * 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US7947717B2 (en) 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
PE20120207A1 (es) 2008-12-03 2012-03-31 Presidio Pharmaceuticals Inc Derivados de naftaleno, como inhibidores de hcv ns5a
EA024853B1 (ru) 2008-12-03 2016-10-31 Пресидио Фармасьютикалс, Инк. Ингибиторы ns5a вгс
CA2755658A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
NZ599373A (en) 2009-11-14 2013-04-26 Hoffmann La Roche Biomarkers for predicting rapid response to hcv treatment
SG181104A1 (en) 2009-12-02 2012-07-30 Hoffmann La Roche Biomarkers for predicting sustained response to hcv treatment
US20130065897A1 (en) * 2009-12-23 2013-03-14 Peter Maccallum Cancer Institute Compounds, preparation and uses thereof
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
KR101159000B1 (ko) * 2010-06-18 2012-06-21 (주) 에빅스젠 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물
US9023876B2 (en) 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
US9255088B2 (en) 2010-08-11 2016-02-09 The Regents Of The University Of California Premature-termination-codons readthrough compounds
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
RU2014117587A (ru) 2011-10-10 2015-11-20 Ф. Хоффманн-Ля Рош Аг Противовирусные соединения
KR20140104030A (ko) 2011-12-16 2014-08-27 에프. 호프만-라 로슈 아게 Hcv ns5a의 억제제
PL2794629T3 (pl) 2011-12-20 2018-02-28 Riboscience Llc 2',4'-difluoro-2'-metylo-podstawione pochodne nukleozydowe jako inhibitory replikacji rna hcv
BR112014015066A2 (pt) 2011-12-20 2017-06-13 Hoffmann La Roche derivados de nucleosídeos 4'azido-3'-flúor substituídos como inibidores de replicação do rna de hcv
CA2857262A1 (en) 2012-02-24 2013-08-29 F. Hoffmann-La Roche Ag Antiviral compounds
EP2828249B1 (de) 2012-03-23 2018-10-10 The Regents of The University of California Verbindungen für durchlesen von codons mit vorzeitigem abschluss
CA2882853C (en) 2012-04-20 2021-11-23 Vineet Gupta Compounds and methods for regulating integrins
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
CA2892589A1 (en) 2013-01-23 2014-07-31 F. Hoffmann-La Roche Ag Antiviral triazole derivatives
US9428469B2 (en) 2013-03-05 2016-08-30 Hoffmann-La Roche Antiviral compounds
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
MX2015015781A (es) 2013-05-16 2016-06-02 Riboscience Llc Derivados de nucleósido 4'-azido, 3'-deoxi-3'-fluoro sustituido.
US9895442B2 (en) 2013-05-16 2018-02-20 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
CA3075645A1 (en) 2017-09-21 2019-03-28 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
KR101893988B1 (ko) 2018-05-16 2018-08-31 (주)에빅스젠 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물
WO2023161427A1 (en) 2022-02-24 2023-08-31 Eisbach Bio Gmbh Viral combination therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021934A1 (en) * 1992-05-01 1993-11-11 Commonwealth Scientific And Industrial Research Organisation Heteropolytungstates in the treatment of flavivirus infections
WO1998020013A1 (de) * 1996-11-07 1998-05-14 Andreas Johannes Kesel Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909467A (en) * 1958-07-09 1959-10-20 Us Vitamin Pharm Corp 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione
US3888984A (en) * 1972-03-13 1975-06-10 Lilly Industries Ltd Oxazole and imidazole derivatives as antifungal agents
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
CA2153553A1 (en) * 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021934A1 (en) * 1992-05-01 1993-11-11 Commonwealth Scientific And Industrial Research Organisation Heteropolytungstates in the treatment of flavivirus infections
WO1998020013A1 (de) * 1996-11-07 1998-05-14 Andreas Johannes Kesel Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0010573A1 *

Also Published As

Publication number Publication date
AU743411B2 (en) 2002-01-24
JP2002523371A (ja) 2002-07-30
CN1325309A (zh) 2001-12-05
AU5570299A (en) 2000-03-14
WO2000010573A1 (en) 2000-03-02
IL141456A0 (en) 2002-03-10
BR9913157A (pt) 2001-05-15
EP1128832A1 (de) 2001-09-05
CA2341970A1 (en) 2000-03-02
ID27787A (id) 2001-04-26
KR20010099623A (ko) 2001-11-09

Similar Documents

Publication Publication Date Title
EP1128832A4 (de) Verbindungen, zusammenstellungen und methoden zur phophylaxe und behandlung von viralen infektionen und damit verbundenen erkrankungen
EP1109580A4 (de) Verfahren zur behandlung oder prävention viraler infektionen und damit einhergehenden erkrankungen
EP1115286A4 (de) Verfahren zur behandlung und vorbeugung viraler infektionen und damit verbundener erkrankungen
AU1099000A (en) Novel compounds and compositions for treating hepatitis c infections
HK1023371A1 (en) Compositions and methods for treating viral infections
IL139002A0 (en) Compositions for the treatment of hiv and other viral infections
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
EP1051169A4 (de) Verbindungen, zusammenstellungen und methoden zur behandlung von pneumoviralen infektionen und damit verbundene krankheiten
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
EP0920419A4 (de) Verbindungen, zusammensetzungen und methoden zur behandlung von grippe
AU7165498A (en) Methods for treating viral infections
AU5006499A (en) Compositions and methods for the treatment or prevention of pulmonary infections
AU2002324753A1 (en) Composition and method for treating viral infection
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
EP1135137A4 (de) Copolymerzusammenstellungen zur behandlung von viralen infektionen
IL133760A0 (en) Composition for the treatment of dandruff
IL128351A0 (en) Pharmaceutical composition for treating viral diseases
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
IL140417A0 (en) NOVEL COMPOUNDS DERIVED FROM β-D-XYLOSE, PREPARATION METHOD AND THERAPEUTIC USE
AU6798000A (en) Compounds, compositions and methods for treating influenza
AU3698199A (en) Radioimmuno-pharmacon for treating the hiv-1 infection
ZA200004856B (en) Treatment of panic attacks.
HUP9900123A3 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof
EP1027352A4 (de) Antibakterielle carbapenem-verbindungen, zusammensetzungen und behandlungsmethoden

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030122

17Q First examination report despatched

Effective date: 20040226

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040908